LIFARIZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H32N4
Molecular Weight	436.5912
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)N=C(N1)C5=CC=C(C)C=C5

InChI

InChIKey=HTDFEXRUDGWNHA-UHFFFAOYSA-N

InChI=1S/C29H32N4/c1-22-13-15-26(16-14-22)29-30-23(2)27(31-29)21-32-17-19-33(20-18-32)28(24-9-5-3-6-10-24)25-11-7-4-8-12-25/h3-16,28H,17-21H2,1-2H3,(H,30,31)

HIDE SMILES / InChI

Molecular Formula	C29H32N4
Molecular Weight	436.5912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8733590 | https://www.ncbi.nlm.nih.gov/pubmed/7834213 | https://www.ncbi.nlm.nih.gov/pubmed/9502174 | https://adisinsight.springer.com/drugs/800003892

Lifarizine is a use- and voltage-dependent antagonist of human voltage sensitive sodium currents. Lifarizine inhibited both the plateau and the spike phases of the Ca2+ increases suggesting that, in addition to its known sodium channel blocking properties, it may also inhibit more than one class of calcium channel in the synaptosomes. Lifarizine reduced both infarct area and volume in the mouse with middle cerebral artery occlusion. Lifarizine was in phase II for the treatment of stroke but this investigation was discontinued.

Approval Year

PubMed

Title	Date	PubMed
Reasons why stroke trials underestimate the neuroprotective effects of drugs.	2002-01	11779937
Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics.	2000-05-05	10796057
Focal cerebral ischemia in the mouse: hypothermia and rapid screening of drugs.	1998-02	9502174
Inhibition by lifarizine of intracellular Ca2+ rises and glutamate exocytosis in depolarized rat cerebrocortical synaptosomes and cultured neurones.	1996-05	8733590
Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat survival model of 2 vessel occlusion.	1995-12	8719782
Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group.	1995-09-15	7486628
Selectivity of the neuroprotective agent lifarizine.	1995-09	7482992
MR evaluation of calcium entry blockers with putative cerebroprotective effects in acute cerebral ischaemia.	1990	2089909

Patents

Sample Use Guides

In Vivo Use Guide

Single dose 100 mg/kg

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:21:49 GMT 2025` Edited by `admin` on `Mon Mar 31 18:21:49 GMT 2025`
Record UNII	C3705I245K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LIFARIZINE

Official Name

English

RS-87476-000

Preferred Name

English

1-(DIPHENYLMETHYL)-4-((5-METHYL-2-P-TOLYLIMIDAZOL-4-YL)METHYL)PIPERAZINE

Common Name

English

PIPERAZINE, 1-(DIPHENYLMETHYL)-4-((5-METHYL-2-(4-METHYLPHENYL)-1H-IMIDAZOL-4-YL)METHYL)-

Systematic Name

English

LIFARIZINE [USAN]

Common Name

English

lifarizine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333